)
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Sohini Das writes on automobile and healthcare sectors for Business Standard. Over her 17 years as a journalist, she has covered multiple sectors and issues -- FMCG, dairy, tourism, and state elections, among others, across Kolkata, Ahmedabad, and Mumbai. She loves doing personality stories and ground reportage.
Allocation jumps 118% over RE to Rs 2.23 trillion; Rs 35,000 cr earmarked for Covid vaccination
New central scheme called Atmanirbhar Swasth Bharat Yojana gets Rs 64,180 crore in Sitharaman's budget
The company has now decided to focus on specialty drugs. The annual price cuts made the Japanese generics market unattractive
The total revenue from operations came in at Rs 5,169 crore and the net profit stood at Rs 748 crore, up 113 per cent.
The company has repaid debt of about $490 million in 9MFY21; filings for 90 ANDAs await US FDA approval
DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment.
The bridge trials on 1,600 participants in India was ongoing. The phase 2 trials are completed and the phase 3 is on.
The trial has assessed its efficacy during a period with high transmission and with a new UK strain of the virus
ZyCoV-D can remain stable at 25 degrees Celsius for months
The genome of the UK-variant has 17 mutations, eight of those were in the spike protein domain
To raise manufacturing capacity by 30% over next 2 months from present 2.4 mn doses
NeuroRx and Relief Therapeutics have partnered to develop a drug called RLF-100 that has anti-inflammatory and anti-cytokine activity properties.
Around November, IIL had indicated that it was open to discussions with the US major.
SII Chief Executive Officer Adar Poonawalla earlier indicated legal indemnity was required to ensure that the vaccination drive could be completed smoothly
India may start vaccine exports as soon as today
The vaccine manufacturer is making preparations and working on necessary regulatory protocols
Also wait for instructions from the Centre on the second phase of the drive
As for Serum Institute of India's Covishield approval, the drug regulator has mentioned in conditions to be met that the firm has to submit an India-specific risk management plan
Govt unlikely to take a shot at Covid-19 vaccine liability, say legal experts
Quantum of doses to be exported not known